Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 4:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 909 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Neoplasms, Hematologic Neoplasms, Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
138
States / cities
Birmingham, Alabama • Athens, Georgia • Augusta, Georgia + 107 more
Conditions
Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blasts Under 25 Percent of Bone Marrow Nucleated Cells, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Burkitt Leukemia, Chronic Monocytic Leukemia, Lymphoblastic Lymphoma, Mast Cell Leukemia, Myeloproliferative Neoplasm
Interventions
Total-Body Irradiation, Thiotepa, Fludarabine, Cyclophosphamide, Busulfan, Allogeneic Bone Marrow Transplantation, Tacrolimus, Methotrexate, Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation, Echocardiography, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
Radiation · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 26 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Atlanta, Georgia • Iowa City, Iowa + 5 more
Conditions
Chronic Kidney Diseases
Interventions
Dietary education program
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Rochester, New York
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Colorectal Adenocarcinoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v6, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
10
States / cities
Gilbert, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 6 more
Recruiting No phase listed Observational

Muscle Recovery After Critical Illness

NCT05537298
Conditions
ICU Acquired Weakness, Post Intensive Care Unit Syndrome, Muscle Weakness, Critical Illness
Interventions
Not listed
Lead sponsor
Esther Dupont-Versteegden
Other
Eligibility
18 Years and older · Male only
Enrollment
209 participants
Timeline
2022 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Lexington, Kentucky • Oklahoma City, Oklahoma
Completed No phase listed Observational

RBC Irradiation, Anemia and Gut Injury

NCT02741648
Conditions
Anemia, Necrotizing Enterocolitis
Interventions
Near Infrared Spectroscopy, Non-invasive Image-based Anemia Assessment
Device · Other
Lead sponsor
Emory University
Other
Eligibility
1 Day to 5 Days
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant for Bone Marrow Failure Syndromes

NCT00176878
Conditions
Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
Interventions
Stem cell transplant, Fludarabine monophosphate, Total lymphoid irradiation, Busulfan, anti-thymocyte globulin
Procedure · Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Mantle Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human
Procedure · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 70 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
374
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 236 more
Conditions
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 4 Interventional Results available

Fibrinolytic Therapy Versus Medical Thoracoscopy

NCT03213834
Conditions
Pleural Diseases
Interventions
Chest thoracoscopy, Chest fibrinolytic therapy, tPA, DNase
Procedure · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Pathologic Stage 0 Cutaneous Melanoma AJCC v8, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Best Practice, Biospecimen Collection, Endoscopic Procedure, Fecal Microbiota Transplantation, Infliximab, Laboratory Biomarker Analysis, Prednisone, Vedolizumab
Other · Procedure · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Arthritis
Interventions
Blood samples, Synovial fluid aspiration, Synovial tissue sample
Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Frederick, Maryland • Wyomissing, Pennsylvania • Jackson, Tennessee
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Chromophobe Renal Cell Carcinoma, Clear Cell Papillary Renal Tumor, Clear Cell Renal Cell Carcinoma, Kidney Oncocytoma, Papillary Renal Cell Carcinoma, Urothelial Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1655
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more
Conditions
Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Recurrent Bladder Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Stage, Colon Cancer, Stage I-III Colon Cancer, Stage IV Colon Cancer With Resectable Liver Metastases
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Heart Failure
Interventions
Blood Sample, Stool Sample
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
40 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Inflammatory Bowel Disease, Crohn Disease
Interventions
Coronal T1 weighted spin echo images, Spin-lattice relaxation (T1), Magnetic resonance spectroscopy, Blood Draw
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 20 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions
BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Galveston, Texas • Houston, Texas
Conditions
Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
Interventions
Treosulfan, Fludarabine Phosphate, Tacrolimus, Methotrexate, Lapine T-Lymphocyte Immune Globulin, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Quality-of-Life Assessment, Echocardiography, Multigated Acquisition Scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, X-Ray Imaging, Computed Tomography
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 49 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 20 more